Trials / Recruiting
RecruitingNCT06527495
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Clinical Pharmacogenetic Study of the Efficacy and Safety of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Assiut University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The current study will aim to maximize the therapeutic effect and to minimize the adverse effects of sorafenib in HCC through pharmacogenomic analysis of VEGFA and KDR genetic polymorphisms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | Sorafenib Tablets (200 -400 mg) twice daily |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2024-07-30
- Last updated
- 2024-07-30
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06527495. Inclusion in this directory is not an endorsement.